ABSTRACT
We investigated whether coronary flow reserve (CFR) can be modified by tadalafil, a long-acting phosphodiesterase 5 (PDE5) inhibitor, in patients with documented coronary artery disease (CAD). CFR was non-invasively evaluated in 12 men with a positive history for erectile dysfunction (ED) and angiographically documented CAD, in the distal portion of the left anterior descending coronary artery, free from critical stenosis, with contrast enhanced echocardiography at time zero (T0). Then, after 20 mg tadalafil was orally administered CFR measurement was repeated after 2 h (T1) and after 24 h (T2). Doppler curves suitable for the analysis were obtained in all patients (CFR feasibility: 100%). The peak diastolic velocity after adenosine infusion increased from 71.3+/-14.3 cm/s at T0 to 82.5+/-24.0 at T1 (P=NS) and to 89.5+/-21.1 at T2 (P=0.0010). CFR after tadalafil increased significantly from 2.6+/-0.3 at T0 to 3.1+/-0.7 at T1 (P=0.0078) and a further increment was found at T2 (3.5+/-0.9; P=0.0010 vs T0). Our study shows that oral administration of tadalafil exerts a long standing, potentially beneficial effect on coronary microvasculature in patients with ED.
Subject(s)
Carbolines/pharmacology , Coronary Stenosis/physiopathology , Coronary Vessels/drug effects , Erectile Dysfunction/drug therapy , Phosphodiesterase Inhibitors/pharmacology , Adult , Aged , Blood Flow Velocity , Coronary Angiography , Coronary Stenosis/complications , Echocardiography , Erectile Dysfunction/complications , Hemodynamics , Humans , Male , Microcirculation/drug effects , Middle Aged , Tadalafil , Time FactorsABSTRACT
An isolated ventricular diverticulum in an adult patient investigated for chest pain is reported. An exhaustive diagnosis was obtained by different means and complementary imaging techniques such as echocardiography, cardiovascular magnetic resonance imaging and cineangiography.
Subject(s)
Diagnostic Imaging , Heart Aneurysm/diagnosis , Adult , Cardiomyopathies/diagnosis , Cineangiography , Diverticulum/diagnosis , Echocardiography, Doppler, Color , Electrocardiography , Electrocardiography, Ambulatory , Humans , Magnetic Resonance Imaging , MaleABSTRACT
Hormone replacement therapy (HRT) was initially given to protect women against osteoporosis and alleviate menopausal symptoms, such as hot flashes, depression, sleep disturbances, and vaginal dryness. In view of the understanding of oestrogen deficiency as a major trigger for the acceleration of cardiovascular risk after menopause, HRT may also be proposed as a substantial beneficial cardioprotective agent. Progestins, which may be added to oestrogen in combined HRT to reduce the risk of uterine malignancy, have a number of potential adverse effects on the cardiovascular system which could even attenuate the benefit of unopposed oestrogen replacement therapy in post-menopausal women.
